TCGA-A7-A0CH-01A-21R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 36
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- ANDROGEN_RESPONSE+0.290
- UV_RESPONSE_DN+0.230
- FATTY_ACID_METABOLISM+0.220
- OXIDATIVE_PHOSPHORYLATION+0.220
- BILE_ACID_METABOLISM+0.140
- HEME_METABOLISM+0.140
- TGF_BETA_SIGNALING+0.140
- PEROXISOME+0.130
- NOTCH_SIGNALING+0.120
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.460
- E2F_TARGETS-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- MYC_TARGETS_V2-0.380
- IL6_JAK_STAT3_SIGNALING-0.320
- INTERFERON_ALPHA_RESPONSE-0.320
- INFLAMMATORY_RESPONSE-0.310
- ANGIOGENESIS-0.290
- G2M_CHECKPOINT-0.290
- IL2_STAT5_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A27P-01A-11R-A16F-07 | — | B | 0.849 |
| 2 | SRR8613744 | — | F | 0.828 |
| 3 | SRR6013557 | — | cohortA1 | 0.818 |
| 4 | 20030017.LumA | — | B | 0.817 |
| 5 | SRR1516042 | — | — | 0.811 |
| 6 | C3L-01889 | — | cohortA2 | 0.795 |
| 7 | MDT-AP-0180 | Med | Medulloblastoma | 0.793 |
| 8 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.793 |
| 9 | TCGA-A7-A26E-01A-11R-A169-07 | — | B | 0.792 |
| 10 | TCGA-BH-A0E7-01A-11R-A034-07 | — | B | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |